SCHEMBL424570

SCHEMBL424570

CC1OCCN1C(=O)n1cnc(-c2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.44
CES2 O00748 1/20 0.38
USP19 O94966 2/20 0.37
USP30 Q70CQ3 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
DAGLA Q9Y4D2 1/20 0.35
PLAUR Q03405 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
HTT P42858 3/20 0.34
LMNA P02545 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
TSHR P16473 1/20 0.34
PIN1 Q13526 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427555 0.79 FAAH (0.46) FAAHCES2USP19DAGLAHTT
SCHEMBL425716 0.77 L3MBTL1 (0.42) FAAHUSP19USP30LMNAKDM4E
SCHEMBL426612 0.76 ALDH1A1 (0.51) PLAURHTTLMNAKDM4EALDH1A1
SCHEMBL17460215 0.76 FAAH (0.47) FAAHNPC1RAB9A
SCHEMBL427480 0.74 FAAH (0.46) FAAHCES2USP19HTTLMNA
SCHEMBL424684 0.74 ALDH1A1 (0.45) FAAHPLAURHTTLMNAKDM4E
SCHEMBL425869 0.74 FAAH (0.43) FAAHCES2USP19HTTLMNA
SCHEMBL425924 0.74 FAAH (0.46) FAAHCES2USP19DRD2DRD4
SCHEMBL19294003 0.73 CHRNA7 (0.46) FAAHCES2
SCHEMBL10645106 0.72 FAAH (0.56) FAAHCES2KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885USP19 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.